Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Cancer Research |
| Vol/bind | 70 |
| Udgave nummer | 7 |
| Sider (fra-til) | 2984-93 |
| Antal sider | 9 |
| DOI | |
| Status | Udgivet - apr. 2010 |
Bibliografisk note
Keywords: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; DNA Repair; DNA-Directed DNA Polymerase; Dacarbazine; Gene Knockdown Techniques; Hela Cells; Histones; Humans; Infrared Rays; Neoplasms; RNA, Small Interfering; Radiation Tolerance; TransfectionAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
I: Cancer Research, Bind 70, Nr. 7, 04.2010, s. 2984-93.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown
AU - Higgins, Geoff S
AU - Prevo, Remko
AU - Lee, Yin-Fai
AU - Helleday, Thomas
AU - Muschel, Ruth J
AU - Taylor, Steve
AU - Yoshimura, Michio
AU - Hickson, Ian David
AU - Bernhard, Eric J
AU - McKenna, W Gillies
N1 - Keywords: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; DNA Repair; DNA-Directed DNA Polymerase; Dacarbazine; Gene Knockdown Techniques; Hela Cells; Histones; Humans; Infrared Rays; Neoplasms; RNA, Small Interfering; Radiation Tolerance; Transfection
PY - 2010/4
Y1 - 2010/4
N2 - The effectiveness of radiotherapy treatment could be significantly improved if tumor cells could be rendered more sensitive to ionizing radiation (IR) without altering the sensitivity of normal tissues. However, many of the key therapeutically exploitable mechanisms that determine intrinsic tumor radiosensitivity are largely unknown. We have conducted a small interfering RNA (siRNA) screen of 200 genes involved in DNA damage repair aimed at identifying genes whose knockdown increased tumor radiosensitivity. Parallel siRNA screens were conducted in irradiated and unirradiated tumor cells (SQ20B) and irradiated normal tissue cells (MRC5). Using gammaH2AX foci at 24 hours after IR, we identified several genes, such as BRCA2, Lig IV, and XRCC5, whose knockdown is known to cause increased cell radiosensitivity, thereby validating the primary screening end point. In addition, we identified POLQ (DNA polymerase ) as a potential tumor-specific target. Subsequent investigations showed that POLQ knockdown resulted in radiosensitization of a panel of tumor cell lines from different primary sites while having little or no effect on normal tissue cell lines. These findings raise the possibility that POLQ inhibition might be used clinically to cause tumor-specific radiosensitization.
AB - The effectiveness of radiotherapy treatment could be significantly improved if tumor cells could be rendered more sensitive to ionizing radiation (IR) without altering the sensitivity of normal tissues. However, many of the key therapeutically exploitable mechanisms that determine intrinsic tumor radiosensitivity are largely unknown. We have conducted a small interfering RNA (siRNA) screen of 200 genes involved in DNA damage repair aimed at identifying genes whose knockdown increased tumor radiosensitivity. Parallel siRNA screens were conducted in irradiated and unirradiated tumor cells (SQ20B) and irradiated normal tissue cells (MRC5). Using gammaH2AX foci at 24 hours after IR, we identified several genes, such as BRCA2, Lig IV, and XRCC5, whose knockdown is known to cause increased cell radiosensitivity, thereby validating the primary screening end point. In addition, we identified POLQ (DNA polymerase ) as a potential tumor-specific target. Subsequent investigations showed that POLQ knockdown resulted in radiosensitization of a panel of tumor cell lines from different primary sites while having little or no effect on normal tissue cell lines. These findings raise the possibility that POLQ inhibition might be used clinically to cause tumor-specific radiosensitization.
U2 - 10.1158/0008-5472.CAN-09-4040
DO - 10.1158/0008-5472.CAN-09-4040
M3 - Journal article
C2 - 20233878
SN - 0576-6656
SN - 1538-7445
VL - 70
SP - 2984
EP - 2993
JO - Cancer Research
JF - Cancer Research
IS - 7
ER -